Multicenter study for the effect preserving renal function of HMG-CoA reductase inhibitor (simvastatin) in type 2 diabetic nephropathy with hyperlipidemia (MIDN Study)
- Conditions
- Type 2 diabetic nephropathy with hyperlipidemia
- Registration Number
- JPRN-C000000370
- Lead Sponsor
- Japanese Society of Kidney and Lipids
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Not provided
1) Type 1 diabetes mellitus. 2) The subject has cardio-vascular complications as follows: receiving coronary artery bypass grafting (CABG) or percutaneous transluminal coronary angioplasty (PTCA) within 3 months; unstable angina; myocardial infarction; transient ischemic attack (TIA) within 6 months, congestive heart failure classified into class III or IV of New York Heart Association (NYHA); cerebral infarction within 3months. 3) The subject has non diabetic nephropathy such as chronic glomerulonephritis, nephrotic syndrome and polycystic kidney. 4) The subject's serum creatinine is more than 2.5mg/dL. 5) The subject has secondary hypertension except that due to diabetes. 6) The subject's HbA1c is more than 9%. 7) The subject is inappropriate for participation in the study for other reasons, as determined by an investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method